Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 5/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1005428 | 0.90 | SCD (0.47) | SCDGPR119CSNK2A1FPR2PROKR1 | |
| SCHEMBL12239172 | 0.85 | SMN1; SMN2 (0.43) | SCDGPR119CSNK2A1 | |
| SCHEMBL12239187 | 0.85 | CSNK2A1 (0.45) | SCDGPR119CSNK2A1 | |
| SCHEMBL12239176 | 0.85 | CSNK2A1 (0.45) | SCDGPR119CSNK2A1FPR2PROKR1 | |
| SCHEMBL12239186 | 0.85 | SCD (0.42) | SCDGPR119CSNK2A1 | |
| SCHEMBL1006023 | 0.84 | GPR119 (0.47) | SCDGPR119FPR2PROKR1KCNH2 | |
| SCHEMBL12239188 | 0.84 | GPR119 (0.42) | SCDGPR119CSNK2A1 | |
| SCHEMBL12262498 | 0.84 | SCN8A (0.42) | SCDGPR119CSNK2A1 | |
| SCHEMBL1007710 | 0.84 | UTS2R (0.47) | KCNH2 | |
| SCHEMBL1003936 | 0.83 | GPR119 (0.46) | SCDGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263557-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-10-27 | — | — | US | disclosed |
| US-20110263557-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-10-27 | — | — | US | disclosed |
| US-20110263557-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-10-27 | — | — | US | disclosed |
| EP-2271619-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009126535-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009126535-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263557-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR55, NR1H2 | SCD 1145/4885GPR119 1/4885CSNK2A1 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.